{"id":"W4379979778","doi":"10.1002/hon.3166_ot15","title":"PHASE 1 STUDY OF PRT1419 (MCL1 INHIBITOR) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MYELOID OR B‐CELL MALIGNANCIES","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Universitat Autònoma de Barcelona","keywords":"Venetoclax; Medicine; Azacitidine; Tolerability; Internal medicine; Myeloid leukemia; Oncology; Myeloid; Ven; Rituximab; Lymphoma; Cancer research; Leukemia; Chronic lymphocytic leukemia; Adverse effect; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009811779,0.001310757,0.001763598,0.0005691558,0.0003756806,0.0008516163,0.001015322,0.001210809,0.004547963],"category_scores_gemma":[0.0007171117,0.0007415766,0.001256431,0.0004231433,0.0007276741,0.0007950311,0.0003475921,0.002953687,0.0008752084],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007828022,"about_ca_system_score_gemma":0.00147592,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001107305,"about_ca_topic_score_gemma":0.002806031,"domain_scores_codex":[0.9997079,0.0001170106,0.00001165032,0.00007056498,0.00003230324,0.00006055957],"domain_scores_gemma":[0.9996196,0.00004790704,0.0000694006,0.00003411891,0.00002991106,0.0001991134],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6348904,0.1414783,0.005492367,0.001300019,0.001774169,0.000472665,0.0004663755,0.004063503,0.08498069,0.0005764125,0.006300668,0.1182044],"study_design_scores_gemma":[0.4011087,0.5833382,0.006361161,0.00003716443,0.0004128122,0.000350487,0.00005434204,0.001036679,0.004086278,0.0002281734,0.002954651,0.00003139158],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889487,0.002721042,0.0006940198,0.0004786872,0.0001749538,0.003467909,0.001306504,0.0001548107,0.002053396],"genre_scores_gemma":[0.983961,0.002934576,0.002347985,0.0008309572,0.0001653419,0.003096204,0.002721656,0.00004441149,0.003897916],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004547963,"threshold_uncertainty_score":0.01521444,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03958954685764432,"score_gpt":0.3475295426058064,"score_spread":0.3079399957481621,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}